Belvedere Trading
KYMR icon

Belvedere Trading’s Kymera Therapeutics KYMR Stock Holding History

Belvedere Trading’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,282
Closed -$255K – 886
2025
Q4 		$255K Buy
+3,282
New +$222K ﹤0.01% 416
2023
Q1 		– Sell
-7,775
Closed -$194K – 1220
2022
Q4 		$194K Buy
+7,775
New +$207K ﹤0.01% 344

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Belvedere Trading's KYMR Position: Q1 2026 in Review

Belvedere Trading sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 3,282 shares — an estimated $255K sold.

Belvedere Trading first reported a position in KYMR in Q4 2022 and held it in 2 quarters. The position peaked at $255K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Belvedere Trading reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Belvedere Trading sold 3,282 Kymera Therapeutics shares in Q1 2026, an estimated $255K.
  • Belvedere Trading first reported a position in Kymera Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belvedere Trading's Kymera Therapeutics position peaked at $255K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.